
Altrenogest
CAS No. 850-52-2
Altrenogest( Altrenogest | A 35957 | A-35957 | Allyl trenbolone | DRC 6246 | R 2267 | REGU-MATE )
Catalog No. M16177 CAS No. 850-52-2
Altrenogest(A35957; RU2267) is a progestogen structurally related to veterinary steroid trenbolone.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
50MG | 41 | In Stock |
![]() ![]() |
100MG | 58 | In Stock |
![]() ![]() |
200MG | 105 | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameAltrenogest
-
NoteResearch use only, not for human use.
-
Brief DescriptionAltrenogest(A35957; RU2267) is a progestogen structurally related to veterinary steroid trenbolone.
-
DescriptionAltrenogest(A35957; RU2267) is a progestogen structurally related to veterinary steroid trenbolone.(In Vitro):Altrenogest (Allyltrenbolone) is a progestogen structurally related to veterinary steroid trenbolone. Treatment of embryo-recipient mares with Altrenogest (Allyltrenbolone) appears to be beneficial in extending the degree of donor-recipient synchrony required for successful embryo transfer. The oil and gel Altrenogest (Allyltrenbolone) preparations are equally effective in modulating estrous behavior and time to estrus and ovulation. Altrenogest (Allyltrenbolone) treatment started late in diestrus appears to result in a high incidence of ovulation during treatment and when luteolysis and ovulation occur during treatment; the subsequent luteal phase is frequently prolonged due to failure of regression of the CL.
-
In VitroAltrenogest (Allyltrenbolone) is a progestogen structurally related to veterinary steroid trenbolone. Treatment of embryo-recipient mares with Altrenogest (Allyltrenbolone) appears to be beneficial in extending the degree of donor-recipient synchrony required for successful embryo transfer. The oil and gel Altrenogest (Allyltrenbolone) preparations are equally effective in modulating estrous behavior and time to estrus and ovulation. Altrenogest (Allyltrenbolone) treatment started late in diestrus appears to result in a high incidence of ovulation during treatment and when luteolysis and ovulation occur during treatment; the subsequent luteal phase is frequently prolonged due to failure of regression of the CL.
-
In Vivo——
-
SynonymsAltrenogest | A 35957 | A-35957 | Allyl trenbolone | DRC 6246 | R 2267 | REGU-MATE
-
PathwayEndocrinology/Hormones
-
TargetEstrogen Receptor/ERR
-
RecptorER
-
Research AreaEndocrinology
-
Indication——
Chemical Information
-
CAS Number850-52-2
-
Formula Weight310.43
-
Molecular FormulaC21H26O2
-
Purity>98% (HPLC)
-
SolubilityEthanol: 2 mg/mL (6.44 mM); DMSO: 62 mg/mL (199.72 mM)
-
SMILESC[C@@]12[C@@](CC=C)(O)CC[C@@]1([H])[C@]3([H])CCC4=CC(CCC4=C3C=C2)=O
-
Chemical Name(8S,13S,14S,17R)-17-allyl-17-hydroxy-13-methyl-1,2,6,7,8,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-3-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Squires EL, et al. J Anim Sci, 1983, 56(4), 901-910.
molnova catalog



related products
-
Estrogen receptor mo...
Estrogen receptor modulator 1 causes regression of Tamoxifen-resistant, hormone-independent xenograft tumors. Estrogen receptor modulator 1 is an orally active and selective estrogen receptor modulator (SERM) (pIC50: 0.46).
-
(E/Z)-GSK5182?
(E/Z)-GSK5182 is a racemic compound of (E)-GSK5182 and (Z)-GSK5182 isomers.
-
CMP8
CMP8 is a selective ligand for estrogen receptor. CMP8 binds to the mutant estrogen receptor ligand binding domain (ERLBD).